Cargando…

Advances and controversies in the management of early stage non-small cell lung cancer

Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cilleruelo-Ramos, Angel, Cladellas-Gutiérrez, Esther, de la Pinta, Carolina, Quintana-Cortés, Laura, Sosa-Fajardo, Paloma, Couñago, Felipe, Mielgo-Rubio, Xabier, Trujillo-Reyes, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716990/
https://www.ncbi.nlm.nih.gov/pubmed/35070733
http://dx.doi.org/10.5306/wjco.v12.i12.1089
_version_ 1784624439757897728
author Cilleruelo-Ramos, Angel
Cladellas-Gutiérrez, Esther
de la Pinta, Carolina
Quintana-Cortés, Laura
Sosa-Fajardo, Paloma
Couñago, Felipe
Mielgo-Rubio, Xabier
Trujillo-Reyes, Juan Carlos
author_facet Cilleruelo-Ramos, Angel
Cladellas-Gutiérrez, Esther
de la Pinta, Carolina
Quintana-Cortés, Laura
Sosa-Fajardo, Paloma
Couñago, Felipe
Mielgo-Rubio, Xabier
Trujillo-Reyes, Juan Carlos
author_sort Cilleruelo-Ramos, Angel
collection PubMed
description Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy. There is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy. Alternative treatments such as stereotactic body radiotherapy and radiofrequency ablation can also produce good outcomes in inoperable patients or patients who refuse surgery.
format Online
Article
Text
id pubmed-8716990
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87169902022-01-20 Advances and controversies in the management of early stage non-small cell lung cancer Cilleruelo-Ramos, Angel Cladellas-Gutiérrez, Esther de la Pinta, Carolina Quintana-Cortés, Laura Sosa-Fajardo, Paloma Couñago, Felipe Mielgo-Rubio, Xabier Trujillo-Reyes, Juan Carlos World J Clin Oncol Opinion Review Complete resection continues to be the gold standard for the treatment of early-stage lung cancer. The landmark Lung Cancer Study Group trial in 1995 established lobectomy as the minimum intervention necessary for the management of early-stage non-small cell lung cancer, as it was associated with lower recurrence and metastasis rates than sublobar resection and lower postoperative morbidity and mortality than pneumonectomy. There is a growing tendency to perform sublobar resection in selected cases, as, depending on factors such as tumor size, histologic subtype, lymph node involvement, and resection margins, it can produce similar oncological results to lobectomy. Alternative treatments such as stereotactic body radiotherapy and radiofrequency ablation can also produce good outcomes in inoperable patients or patients who refuse surgery. Baishideng Publishing Group Inc 2021-12-24 2021-12-24 /pmc/articles/PMC8716990/ /pubmed/35070733 http://dx.doi.org/10.5306/wjco.v12.i12.1089 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Opinion Review
Cilleruelo-Ramos, Angel
Cladellas-Gutiérrez, Esther
de la Pinta, Carolina
Quintana-Cortés, Laura
Sosa-Fajardo, Paloma
Couñago, Felipe
Mielgo-Rubio, Xabier
Trujillo-Reyes, Juan Carlos
Advances and controversies in the management of early stage non-small cell lung cancer
title Advances and controversies in the management of early stage non-small cell lung cancer
title_full Advances and controversies in the management of early stage non-small cell lung cancer
title_fullStr Advances and controversies in the management of early stage non-small cell lung cancer
title_full_unstemmed Advances and controversies in the management of early stage non-small cell lung cancer
title_short Advances and controversies in the management of early stage non-small cell lung cancer
title_sort advances and controversies in the management of early stage non-small cell lung cancer
topic Opinion Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716990/
https://www.ncbi.nlm.nih.gov/pubmed/35070733
http://dx.doi.org/10.5306/wjco.v12.i12.1089
work_keys_str_mv AT cillerueloramosangel advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT cladellasgutierrezesther advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT delapintacarolina advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT quintanacorteslaura advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT sosafajardopaloma advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT counagofelipe advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT mielgorubioxabier advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer
AT trujilloreyesjuancarlos advancesandcontroversiesinthemanagementofearlystagenonsmallcelllungcancer